Clinical Benefit Analysis of Combination of Edaravone Dexborneol Combined with Butylphthalide in Treatment of Acute Cerebral Infarction
Objective To explore the improvement effect of edaravone dexborneol combined with butylphthalide on cerebral blood circulation in treatment of acute cerebral infarction. Methods Data (54 cases) were chosen from January 2021 to July 2023,including patients with cerebral infarction in Huangmei County People's Hospital. The paper divided them into the control group (27 cases,with routine treatment+sodium butylphthalide chloride injection) and the study group (27 cases,concentrated solution of edaravone dexborneol injection based on the control group) with randomized number table method for prospective analysis. Both groups were treated for 2 weeks,various clinical indicators were compared between two groups. Results Total clinical effective rate of the study group was significantly higher than the control group. After 2 weeks of treatment,both groups showed an increasing trend in Qmin,Vmin,CVR levels,and ADL scores compared with before treatment,those of the study group were higher than the control group. NIHSS and mRS scores showed a decreasing trend,those of the study group were lower than the control group (P＜0.05). Conclusion Edaravone dexborneol combined with butylphthalide is beneficial for improving cerebral blood circulation levels,reducing neurological damage,improving disability,enhancing self-care ability,and further improving clinical effect of patients with acute cerebral infarction.
Acute cerebral infarctionButylphthalideEdaravone dexborneolCerebral blood circulationNeurological function
万方数据
维普
